- Home
- ABOS vs TNYA Comparison
ABOS vs TNYA Comparison
Compare ABOS & TNYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABOS
- TNYA
- Stock Information
- Founded
- ABOS 1996
- TNYA 2016
- Country
- ABOS United States
- TNYA United States
- Employees
- ABOS N/A
- TNYA N/A
- Industry
- ABOS Biotechnology: Pharmaceutical Preparations
- TNYA Medicinal Chemicals and Botanical Products
- Sector
- ABOS Health Care
- TNYA Health Care
- Exchange
- ABOS Nasdaq
- TNYA Nasdaq
- Market Cap
- ABOS 66.6M
- TNYA 74.5M
- IPO Year
- ABOS 2021
- TNYA 2021
- Fundamental
- Price
- ABOS $0.98
- TNYA $0.39
- Analyst Decision
- ABOS Strong Buy
- TNYA Strong Buy
- Analyst Count
- ABOS 3
- TNYA 6
- Target Price
- ABOS $7.33
- TNYA $8.60
- AVG Volume (30 Days)
- ABOS 215.0K
- TNYA 2.1M
- Earning Date
- ABOS 05-13-2025
- TNYA 05-07-2025
- Dividend Yield
- ABOS N/A
- TNYA N/A
- EPS Growth
- ABOS N/A
- TNYA N/A
- EPS
- ABOS N/A
- TNYA N/A
- Revenue
- ABOS N/A
- TNYA N/A
- Revenue This Year
- ABOS N/A
- TNYA N/A
- Revenue Next Year
- ABOS N/A
- TNYA N/A
- P/E Ratio
- ABOS N/A
- TNYA N/A
- Revenue Growth
- ABOS N/A
- TNYA N/A
- 52 Week Low
- ABOS $0.86
- TNYA $0.39
- 52 Week High
- ABOS $3.92
- TNYA $4.78
- Technical
- Relative Strength Index (RSI)
- ABOS 43.50
- TNYA 31.83
- Support Level
- ABOS $0.96
- TNYA $0.36
- Resistance Level
- ABOS $1.13
- TNYA $0.53
- Average True Range (ATR)
- ABOS 0.08
- TNYA 0.04
- MACD
- ABOS 0.00
- TNYA -0.00
- Stochastic Oscillator
- ABOS 10.71
- TNYA 16.13
About ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.
About TNYA Tenaya Therapeutics Inc.
Tenaya Therapeutics Inc is a preclinical stage biotechnology company focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. It is advancing product candidates from three product platforms: gene therapy, cellular regeneration and precision medicine.